DK2252275T3 - Skabelondannede åbne flokke af anisotrope partikler til forbedret transport ind i lungerne - Google Patents
Skabelondannede åbne flokke af anisotrope partikler til forbedret transport ind i lungerne Download PDFInfo
- Publication number
- DK2252275T3 DK2252275T3 DK09709833.9T DK09709833T DK2252275T3 DK 2252275 T3 DK2252275 T3 DK 2252275T3 DK 09709833 T DK09709833 T DK 09709833T DK 2252275 T3 DK2252275 T3 DK 2252275T3
- Authority
- DK
- Denmark
- Prior art keywords
- particles
- tff
- hfa
- protein
- itz
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Medicinsk formulering til anvendelse i en afmålende dosisinhalator under tryk, hvilken formulering omfatter: en tomrumsfyldt flokkuleret suspension, som omfatter en eller flere flokkulerede partikler af et eller flere aktive midler, der er dannet ved tyndfilmsfrysning, samt et drivmiddel, hvor a) en del af den ene eller flere flokkulerede partikler skabelondannes ved dannelse af en eller flere dråber ved atomisering, og b) den skabelondannede flok bliver mere kompakt ved fordampning af drivmidlet for at danne en porøs partikel til transport dybt ind i lungerne.
2. Medicinsk formulering ifølge krav 1 uden et overfladeaktivt middel til stabilisering af partiklerne.
3. Fremgangsmåde til fremstilling af en medicinsk aerosolsammensætning til en afmålende dosisinhalator under tryk, hvilken fremgangsmåde omfatter trinnene, der går ud på: at danne en tomrumsfyldt flokkuleret suspension, som omfatter en eller flere flokkulerede partikler af et eller flere aktive midler samt et drivmiddel; at skabelondanne mindst en del af den ene eller flere flokkulerede partikler ved dannelse af dråber ved atomisering; og at gøre den skabelondannede flok mere kompakt ved fordampning af drivmidlet for at danne en porøs partikel til transport dybt ind i lungerne; hvor den ene eller flere flokkulerede partikler er dannet ved tyndfilmsfrysning.
4. Fremgangsmåde ifølge krav 3 uden et overfladeaktivt middel til stabilisering af partiklerne.
5. Medicinsk formulering til anvendelse i en tørpulverinhalator, hvilken formulering omfatter: en tomrumsfyldt flok, der omfatter en eller flere flokkulerede partikler af et eller flere aktive midler samt et drivmiddel, hvor en del af den ene eller flere flokkulerede partikler er skabelondannet af forskydningskræfteme i en tørpulverinhalator ved aktivering, så der dannes en skabelondannet flok, hvorved den skabelondannede flok omfatter en eller flere anisotrope partikler med et aspektforhold på over 1 og har aerodynamiske egenskaber for transport dybt ind i lungerne, og hvor den ene eller flere flokkulerede partikler er dannet ved tyndfilmsffysning.
6. Medicinsk formulering ifølge krav 5, hvor det ene eller flere aktive midler omfatter itraconazol, paclitaxel, steroider, astmamedicin, immunsuppressive midler, svampebekæmpende medicin og cancerbekæmpende medicin.
7. Medicinsk formulering ifølge krav 5, hvor det ene eller flere aktive midler omfatter et lægemiddel med lav molekylvægt, et lægemiddel med høj molekylvægt, et peptid, et protein eller en kombination deraf.
8. Porøs medicinsk formulering ifølge krav 5, hvor det ene eller flere aktive midler er valgt blandt et protein, et peptid, et vasomotorisk peptid, en immunglobulin, et immunmodulerende protein, en hæmopoietisk faktor, insulin, en insulinanalog, amylin, et antibiotikum, et antistof, et antigen, en interleukin, et interferon, en erythropoietin, en heparin, et trombolytikum, en antitrypsin, et enzym, en anti-protease, et hormon, en vækstfaktor, en nukleinsyre, et oligonukleotid, et antisense-middel og blandinger deraf.
9. Medicinsk formulering ifølge krav 5, hvor den skabelondannede flok omfatter en eller flere anisotrope partikler med et aspektforhold på 0,02, 0,05, 0,1, 0,2, 0,3, 0,4, 0,5, 0,6, 0,7, 1,3, 1,4, 1,5, 1,6, 1,7, 1,8, 1,9, 2,0, 2,1, 2,2, 2,3, 2,4, 2,5, 2,6, 2,7, 2,8, 2,9, 3,0, 5, 10, 20 eller 50.
10. Medicinsk formulering ifølge krav 5, hvor det ene eller flere aktive midler omfatter natamycin, flucytosin, miconazol, flueonazol, itraconazol, clotrimazol, econazol, miconazol, ravueonazol, oxiconazol, sulconazol, terconazol, tioconazol, fenticonazol, bifonazol, oxiconazol, ketoconazol, isoconazol, tolnaftat, amorolfm, terbinafm, voriconazol, posaconazol, albumin eller de farmakologisk acceptable salte, metalkomplekser eller blandinger deraf.
11. Medicinsk formulering ifølge krav 5, hvor drivmidlet er luft.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2821808P | 2008-02-13 | 2008-02-13 | |
| PCT/US2009/034162 WO2009103035A2 (en) | 2008-02-13 | 2009-02-13 | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2252275T3 true DK2252275T3 (da) | 2018-03-05 |
Family
ID=40955349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09709833.9T DK2252275T3 (da) | 2008-02-13 | 2009-02-13 | Skabelondannede åbne flokke af anisotrope partikler til forbedret transport ind i lungerne |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20090208582A1 (da) |
| EP (1) | EP2252275B1 (da) |
| AU (1) | AU2009214443B2 (da) |
| CA (1) | CA2723314C (da) |
| DK (1) | DK2252275T3 (da) |
| NO (1) | NO2252275T3 (da) |
| WO (1) | WO2009103035A2 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2252275T3 (da) * | 2008-02-13 | 2018-04-28 | ||
| BRPI1011721B1 (pt) | 2009-03-26 | 2021-11-16 | Pulmatrix, Inc | Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares |
| US8506799B2 (en) * | 2009-09-09 | 2013-08-13 | ClearCorp | Suspended particle characterization system for a water processing facility |
| US9248110B2 (en) | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
| WO2011115988A1 (en) * | 2010-03-18 | 2011-09-22 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer |
| US9228785B2 (en) | 2010-05-04 | 2016-01-05 | Alexander Poltorak | Fractal heat transfer device |
| WO2012030664A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| US9433576B2 (en) | 2010-09-29 | 2016-09-06 | Pulmatrix, Inc. | Cationic dry powders |
| AU2011308865B2 (en) | 2010-09-29 | 2017-01-05 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
| WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
| CN104274426A (zh) * | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途 |
| CN104274427A (zh) * | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 格拉司琼气溶胶组合物及其用途 |
| WO2015054280A1 (en) | 2013-10-08 | 2015-04-16 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| PL3107548T3 (pl) | 2014-02-20 | 2022-10-31 | Otitopic Inc. | Suche formulacje w proszku do inhalacji |
| EP4218742A1 (en) | 2014-04-04 | 2023-08-02 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for treating age-related conditions |
| CA2991760A1 (en) | 2014-07-31 | 2016-02-04 | Otitopic Inc. | Dry powder formulations for inhalation |
| KR20170095807A (ko) | 2014-10-07 | 2017-08-23 | 램 테라퓨틱스, 인코포레이티드 | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 |
| WO2016178704A1 (en) * | 2015-05-01 | 2016-11-10 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
| BR112018004069A2 (pt) | 2015-09-01 | 2021-07-13 | First Wave Bio, Inc. | composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit |
| US10550019B2 (en) | 2016-04-08 | 2020-02-04 | OptikTechnik LLC | Automated dosing system and method with light profiling for wastewater filtration system |
| US10830545B2 (en) | 2016-07-12 | 2020-11-10 | Fractal Heatsink Technologies, LLC | System and method for maintaining efficiency of a heat sink |
| KR102408798B1 (ko) | 2016-10-14 | 2022-06-13 | 풀매트릭스 오퍼레이팅 컴퍼니, 인크 | 항진균성 건조 분말 |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| WO2019204568A1 (en) * | 2018-04-20 | 2019-10-24 | Board Of Regents, The University Of Texas System | Apparatus and methods for characterizing plume geometry |
| TW202200121A (zh) | 2020-03-16 | 2022-01-01 | 美商費斯特威弗生技股份有限公司 | 治療方法 |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| JP2023520018A (ja) | 2020-04-01 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ニクロサミドの薬学的組成物 |
| EP4158025A1 (en) | 2020-05-26 | 2023-04-05 | Gradalis, Inc. | Methods for the treatment of viral respiratory infections |
| WO2022055817A1 (en) | 2020-09-09 | 2022-03-17 | Gradalis, Inc. | Composition formulated into inhalable dosage forms for the treatment of lung|tumors |
| EP4337173A1 (en) | 2021-05-12 | 2024-03-20 | TFF Pharmaceuticals, Inc. | Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) |
| KR20240049392A (ko) * | 2021-08-30 | 2024-04-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 단클론성 항체 건조 분말 |
| US20230112800A1 (en) | 2021-08-31 | 2023-04-13 | Board Of Regents, The University Of Texas System | Delayed release niclosamide formulation |
| WO2024059819A2 (en) | 2022-09-15 | 2024-03-21 | Tff Pharmaceuticals, Inc. | Compositions of cannabinoids for delivery by inhalation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| JPH1112197A (ja) | 1997-06-18 | 1999-01-19 | Cosmo Sogo Kenkyusho:Kk | 悪性腫瘍診断剤及び治療剤 |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US6585957B1 (en) * | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US20040176391A1 (en) * | 2002-12-31 | 2004-09-09 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| AR028746A1 (es) | 2000-06-23 | 2003-05-21 | Norton Health Care Ltd | Cartucho de dosis previamente medidas para inhalador de polvo seco accionado por la respiracion, el inhalador y un metodo de provision de dosis previamente medidas de polvo seco |
| JP2003146523A (ja) | 2001-11-15 | 2003-05-21 | Canon Inc | 画像形成装置 |
| WO2003090715A2 (en) * | 2002-04-25 | 2003-11-06 | Nektar Therapeutics Uk Ltd | Particulate materials |
| GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| EP1556018A1 (en) * | 2002-09-30 | 2005-07-27 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| EP1589948A1 (en) | 2003-01-15 | 2005-11-02 | Dow Global Technologies Inc. | Drug particles obtained by freezing onto a cold surface |
| EP1663159A4 (en) * | 2003-09-10 | 2010-06-09 | Map Pharmaceuticals Inc | AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION |
| EP1789018A1 (en) | 2004-08-27 | 2007-05-30 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| NO2252275T3 (da) * | 2008-02-13 | 2018-04-28 |
-
2009
- 2009-02-13 NO NO09709833A patent/NO2252275T3/no unknown
- 2009-02-13 CA CA2723314A patent/CA2723314C/en active Active
- 2009-02-13 EP EP09709833.9A patent/EP2252275B1/en active Active
- 2009-02-13 AU AU2009214443A patent/AU2009214443B2/en active Active
- 2009-02-13 WO PCT/US2009/034162 patent/WO2009103035A2/en active Application Filing
- 2009-02-13 DK DK09709833.9T patent/DK2252275T3/da active
- 2009-02-13 US US12/371,573 patent/US20090208582A1/en active Pending
-
2010
- 2010-05-12 US US12/778,795 patent/US10092512B2/en active Active
-
2018
- 2018-08-29 US US16/115,888 patent/US10434062B2/en active Active
-
2019
- 2019-08-29 US US16/555,165 patent/US10660850B2/en active Active
-
2020
- 2020-04-03 US US16/839,957 patent/US11364197B2/en active Active
-
2022
- 2022-05-17 US US17/746,915 patent/US20220354778A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210007971A1 (en) | 2021-01-14 |
| US20100221343A1 (en) | 2010-09-02 |
| AU2009214443A1 (en) | 2009-08-20 |
| AU2009214443B2 (en) | 2013-10-10 |
| US20090208582A1 (en) | 2009-08-20 |
| EP2252275A2 (en) | 2010-11-24 |
| WO2009103035A2 (en) | 2009-08-20 |
| US11364197B2 (en) | 2022-06-21 |
| WO2009103035A3 (en) | 2009-11-12 |
| US20220354778A1 (en) | 2022-11-10 |
| US20200069572A1 (en) | 2020-03-05 |
| US10434062B2 (en) | 2019-10-08 |
| US20190117557A1 (en) | 2019-04-25 |
| NO2252275T3 (da) | 2018-04-28 |
| US10660850B2 (en) | 2020-05-26 |
| CA2723314C (en) | 2017-01-10 |
| EP2252275B1 (en) | 2017-11-29 |
| US10092512B2 (en) | 2018-10-09 |
| EP2252275A4 (en) | 2013-11-06 |
| CA2723314A1 (en) | 2009-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11364197B2 (en) | Compositions and methods of making brittle-matrix particles through blister pack freezing | |
| Lin et al. | Powder production and particle engineering for dry powder inhaler formulations | |
| EP1734938B1 (en) | Insulin highly respirable microparticles | |
| Seville et al. | Spray-dried powders for pulmonary drug delivery | |
| TWI405590B (zh) | 微粉碎化有機化合物粒子之製法 | |
| AU770529B2 (en) | Pharmaceutical aerosol composition containing HFA 227 and HFA 134a | |
| US9724344B2 (en) | Enhanced delivery of drug compositions to treat life threatening infections | |
| US20080038357A1 (en) | Inhalation Powder Containing the CGRP antagonist BIBN4096 and Process for the Preparation Thereof | |
| AU2020250195B2 (en) | Rapamycin Powders for Pulmonary Delivery | |
| Engstrom et al. | Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers | |
| JP2023541585A (ja) | ニクロサミド粒子およびその使用 | |
| Tam et al. | Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers | |
| JP2018535984A (ja) | リバビリンの医薬組成物 | |
| Chan | Inhalation drug delivery devices and emerging technologies | |
| Rowe et al. | Compositions and methods of making brittle-matrix particles through blister pack freezing | |
| AU2003208862A1 (en) | Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof | |
| KR102259824B1 (ko) | 보센탄을 함유한 약학 제제 | |
| Sallam | Recent Advances in the Formulation Development of Inhalational Dosage Forms | |
| Moon et al. | Thin-Film Freeze-Drying Process for Versatile Particles for Inhalation Drug Delivery | |
| Moon et al. | and Robert O. Williams III1 | |
| Durham et al. | Spray dried pyrazinoate salts for tuberculosis therapy |